Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported a higher prevalence of androgenetic alopecia in male respondents compared to female respondents in different regions of Saudi Arabia.

This review discusses the effectiveness of low-level laser therapy for androgenetic alopecia, finding significant increases in hair density and growth for individuals treated with this method.

This study reported that heterozygous carriers of a mutation in the human hairless gene did not differ from healthy homozygotes in the pattern of androgenetic alopecia.

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

This study aimed to identify unknown genetic risk loci associated with androgenetic alopecia by examining SNPs at 12 genomic loci but did not find complete heritable risk factors.

In this review, an association was reported between early-onset androgenetic alopecia and several health conditions like obesity and cardiovascular disease, with genetic and therapeutic research ongoing to improve treatment.

This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.

This study found that androgenetic alopecia causes significant psychological distress, particularly in women, who exhibit a more negative body image and less adaptive functioning compared to controls.

This paper describes pattern or androgenetic alopecia as a genetically defined condition caused by an overreaction to androgens, affecting up to 50% of post-pubertal males and females, characterized by progressive hair loss patterns that differ between genders.

This case report describes two brothers with an unusual, possibly treatment-resistant inflammatory variant of androgenic alopecia, featuring follicular isthmic lymphocytic inflammation and diffuse central scalp hair loss.

AUC and APL are distinct conditions needing careful clinical assessment.

This review discusses the integration of omics analyses in androgenetic alopecia research, reporting no new clinical results but suggesting that collaborative multi-omics studies may enhance understanding of AGA's pathomechanisms.

This research found evidence of inflammatory involvement in androgenetic alopecia, with higher deposition of certain immune components in the scalp of affected patients compared to those without baldness.

This study found that Korean men with androgenetic alopecia have lower hair density and a higher proportion of single-hair units compared to normal adult males.

This paper discusses key mechanisms of androgen metabolism in androgenetic alopecia and reports the effectiveness of treatments like oral finasteride and topical minoxidil, highlighting the limited success rate due to factors like follicular inflammation.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This study found that androgenetic alopecia is significantly associated with moderate impairment of health-related quality of life and emotions, but not with depressive symptoms.

This meta-analysis found that vertex pattern androgenetic alopecia was associated with an increased risk of developing prostate cancer, while other androgenetic alopecia patterns did not show a significant link.

In this study, AMD was observed more frequently in AGA patients, and a higher monocyte/HDL ratio was associated with increased AMD severity, especially in men.

This study revealed that Thai youths who are more worried about androgenetic alopecia tend to experience higher severity of the condition, poorer quality of life, and increased use of multiple hair styling products.

This study found that male patients with androgenetic alopecia were associated with an increased risk of varicose veins, but not other major vascular diseases.

This study found that inhibiting the enzyme PDE8A can promote adipocyte differentiation and enhance hair growth in an animal model of androgenetic alopecia, suggesting PDE8A as a potential therapeutic target for restoring dermal adipogenesis and hair cycling.

In this study, researchers found that heterozygous carriers of a mutation in the hairless gene showed no difference in the pattern of androgenetic alopecia compared to unaffected individuals.

This study suggests that the anogenital distance measure AGD_AC may moderately discriminate the presence of polycystic ovarian syndrome and could be a useful clinical tool.

This review discusses the pathophysiology, molecular events, and therapeutic options for androgenetic alopecia, but reports no new clinical findings.

This study found that arginine deficiency in androgenetic alopecia patients is linked to increased oxidative stress and impaired hair follicle regeneration, with targeted arginine supplementation showing promise as a therapeutic strategy.

This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.

This study at Benha University Hospital found that therapies for male androgenetic alopecia are effective and safe based on a randomized trial involving 40 male patients.

This review discusses the molecular mechanisms of androgenetic alopecia and evaluates current and potential treatments, highlighting the limitations of minoxidil and finasteride and exploring newer approaches like growth factors and cytokines, topical 5-alpha-reductase inhibitors, and platelet-rich plasma injections as more effective and safer alternatives.

HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.